TBPH (Theravance Biopharma) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TBPH Theravance Biopharma Inc TBPH
72 GF Score
Price $16.97
GF Value $16.94
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Theravance Biopharma Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TBPH
72GF Score
Theravance Biopharma Inc TBPH
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theravance Biopharma (TBPH) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be overvalued. The current stock price of $16.97 is trading 0.2% above its estimated GF Value™ of $16.94. GuruFocus considers Theravance Biopharma to be Fairly Valued.

Key valuation signals for TBPH:

  • Short Ratio:
  • GF Value™: $16.94 vs. price of $16.97 (0.2% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges 0TB:Germany
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for TBPH

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.97
Price
$16.94
GF Value